The ‘new, old kids’ on the biotech block unveil a $350M stealth science fund. And they’re going very, very early
Richard Lim and his two co-founders at Cure Ventures have some biotech stories to tell.
Lim recalls the time some 17 years ago he and Lou Tartaglia were going to start something — but then Tartaglia jumped to Third Rock as Kevin Starr and Bob Tepper were ramping things up, with roles at Editas and Agios. He later moved to 5AM. Then there are tales of Dave Fallace’s biotech-naming role at Juno and Denali when Alaska’s most iconic locations provided names for two of his more notable startups at the Alaska Permanent Fund.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.